Floatz logo

Semaglutide

Type 2 Diabetes

Shanghai Jiao Tong University School of Medicineprotein_peptidePhase 4 / ApprovedActive
BBB
75/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
77/ 100
Competitive Position
73/ 100

Competitive context

141 Active assets in the Type 2 Diabetes cohort.

Asset / SponsorPhaseRating
Semaglutide
Shanghai Jiao Tong University School of Medicine
Phase 4BBB
Liraglutide
RenJi Hospital
Phase 4BBB
Exenatide
Vivani Medical, Inc
Phase 4BBB
Dapagliflozin
Bhavya Bhavya, MD
Phase 4BBB
Cotadutide
AstraZeneca
Phase 2BBB

View all 50 →

Same molecule, other indications

Semaglutide is also rated in:

metabolic diseaseDormant
A
Indicative ·
81 / 100
View asset →
type 2 diabetes mellitusDormant
BBB
Indicative ·
79 / 100
View asset →
polycystic ovary syndromeDormant
BBB
Indicative ·
79 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →